Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Quarterly Financial Performance
REGN logo

Regeneron Revenue Climbs 19% to $3.6 Billion Amid Intense Biosimilar Competition

REGN10-QFiling Date: 4/29/2026
Regeneron Pharmaceuticals, Inc.
Description

What this story covers

Regeneron reports 19 percent revenue growth driven by Dupixent and EYLEA HD, despite a 10 percent net income drop. The filing highlights rising R&D costs, manufacturing disruptions, and significant legal challenges regarding patent expirations and government pricing investigations.

Story snapshot

CompanyRegeneron Pharmaceuticals, Inc.
TickerREGN
VariantStandard detailed
Duration13:13
Filing type10-Q
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0000872589-26-000016
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-QView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in